RSV

Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinued COPENHAGEN, Denmark, July 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of…

…

Pivotal…

<!-- Name:DistributionId Value:8780141 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4530 -->…

- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of IVX-A12 (a bivalent of IVX-121 for RSV…